Sporadic ALS Initiation Mechanisms

Sporadic ALS Initiation Mechanisms

Overview

Sporadic amyotrophic lateral sclerosis (sporadic ALS) accounts for approximately 90-95% of all ALS cases and is defined by the absence of a known high-penetrance causal genetic mutation.[@metalinduced2025][@activates2025] Unlike familial ALS, which is linked to specific pathogenic variants in genes such as [C9orf72](/genes/c9orf72), [SOD1](/genes/sod1), [TARDBP](/genes/tardbp), and [FUS](/genes/fus), sporadic ALS arises from a complex interplay of genetic susceptibility variants, environmental exposures, and age-related cellular decline.[@hdac2025]

The fundamental question of what initiates the neurodegenerative cascade in sporadic ALS represents the highest-ranked knowledge gap in the field, with a score of 31/40 across impact, tractability, under-exploration, and data availability dimensions.[@identifying2024] This page synthesizes current understanding of proposed initiation mechanisms and highlights critical open questions.

Sporadic vs. Familial ALS: Key Distinctions

Epidemiological Differences

| Feature | Sporadic ALS | Familial ALS |
|---------|--------------|--------------|
| Proportion of cases | 90-95% | 5-10% |
| Typical onset age | 55-65 years | Earlier (40-60 years) |
| Family history | Absent | Present (autosomal dominant) |
| Known causal gene | None identified | [C9orf72](/entities/c9orf72) (40%), SOD1 (20%), others |
| Phenotypic variability | Broad | Often within families |

Shared Pathological Features

Sporadic ALS Initiation Mechanisms

Overview

Sporadic amyotrophic lateral sclerosis (sporadic ALS) accounts for approximately 90-95% of all ALS cases and is defined by the absence of a known high-penetrance causal genetic mutation.[@metalinduced2025][@activates2025] Unlike familial ALS, which is linked to specific pathogenic variants in genes such as [C9orf72](/genes/c9orf72), [SOD1](/genes/sod1), [TARDBP](/genes/tardbp), and [FUS](/genes/fus), sporadic ALS arises from a complex interplay of genetic susceptibility variants, environmental exposures, and age-related cellular decline.[@hdac2025]

The fundamental question of what initiates the neurodegenerative cascade in sporadic ALS represents the highest-ranked knowledge gap in the field, with a score of 31/40 across impact, tractability, under-exploration, and data availability dimensions.[@identifying2024] This page synthesizes current understanding of proposed initiation mechanisms and highlights critical open questions.

Sporadic vs. Familial ALS: Key Distinctions

Epidemiological Differences

| Feature | Sporadic ALS | Familial ALS |
|---------|--------------|--------------|
| Proportion of cases | 90-95% | 5-10% |
| Typical onset age | 55-65 years | Earlier (40-60 years) |
| Family history | Absent | Present (autosomal dominant) |
| Known causal gene | None identified | [C9orf72](/entities/c9orf72) (40%), SOD1 (20%), others |
| Phenotypic variability | Broad | Often within families |

Shared Pathological Features

Despite different etiologies, sporadic and familial ALS converge on common downstream mechanisms:

• TDP-43 pathology: Aggregates of hyperphosphorylated TDP-43 are found in ~95% of ALS cases, regardless of genetic status[@antisense2025]
• RNA metabolism dysfunction: Abnormal RNA processing is a hallmark of both sporadic and genetic forms[^6]
• Protein homeostasis failure: Ubiquitin-positive inclusions are universal[^7]
• Neuroinflammation: Activated [microglia](/cell-types/microglia-neuroinflammation) and astrocytosis are present in all ALS subtypes[^8]

Proposed Initiation Mechanisms

Multiple competing hypotheses attempt to explain how sporadic ALS is triggered in the absence of high-penetrance mutations. These mechanisms are not mutually exclusive and may represent different pathways to a common endpoint.

1. RNA Metabolism Dysfunction

RNA metabolism dysfunction is emerging as a central initiating event in sporadic ALS. Key observations include:

• Splicing abnormalities: Cryptic exon inclusion and aberrant splicing patterns have been documented in sporadic ALS patient tissues[^9]
• Nuclear import/export defects: Impaired nucleocytoplasmic transport has been observed in sporadic ALS models[@jovicic2015]
• RNA granule formation: Stress granules containing TDP-43 and other RNA-binding proteins accumulate in affected [neurons](/entities/neurons)[@wolozin2019]

2. Stress Granule Dynamics

Stress granules are cytoplasmic RNA-protein assemblies that form in response to cellular stress. In ALS:

• Persistent stress granules: Failure to disassemble stress granules leads to toxic RNA granule accumulation[@protter2016]
• Seeding of aggregates: Stress granules may serve as nucleation sites for TDP-43 aggregation[@kim2013]
• Translation arrest: Prolonged stress granule presence inhibits protein synthesis essential for neuronal survival[@buchan2013]

3. Cytoskeletal Defects

Motor neurons have extremely long axons requiring robust cytoskeletal infrastructure:

• Neurofilament aggregation: Abnormal neurofilament phosphorylation and aggregation disrupts axonal transport[@julien1998]
• Axonal transport impairment: Reduced transport of mitochondria, synaptic components, and signaling molecules precedes motor neuron loss[@de2008]
• Microtubule dysfunction: Post-translational modifications of tubulin affect axonal integrity[@perrot2009]

4. Mitochondrial Dysfunction

Mitochondrial failure is a consistent finding in sporadic ALS:

• Energy crisis: Impaired ATP production compromises neuronal function[@shaw2001]
• Oxidative stress: Increased [reactive oxygen species](/entities/reactive-oxygen-species) damage cellular components[@barber2006]
• Calcium dysregulation: Mitochondrial calcium handling abnormalities affect excitability[@damiano2051]
• Mitophagy defects: Impaired removal of damaged mitochondria accelerates cellular decline[@chen2020]

5. Neuroinflammation

Chronic neuroinflammation is both a cause and consequence of neuronal dysfunction:

• Microglial activation: Pro-inflammatory microglia release cytokines that damage motor neurons[@liao2022]
• Astrocytosis: Reactive [astrocytes](/entities/astrocytes) lose supportive functions and gain toxic properties[@yamanaka2008]
• Peripheral immune infiltration: T cells and other immune cells penetrate the CNS in ALS[@zrzavy2017]
• [Blood-brain barrier](/entities/blood-brain-barrier) disruption: Impaired barrier function allows peripheral immune access[@garbuzovadavis2020]

6. Oligogenic and Polygenic Susceptibility

Emerging evidence suggests sporadic ALS may involve multiple susceptibility variants:

• Rare variant accumulation: Whole-exome studies identify rare variants in ALS-relevant genes in sporadic cases[@van2017]
• Common variant risk: GWAS has identified over 50 loci associated with ALS risk[@nicolas2021]
• Gene-environment interactions: Genetic susceptibility may require environmental triggers for disease expression[@alchalabi2013]

7. Epigenetic Alterations

Age-related epigenetic changes may contribute to sporadic ALS initiation:

• [DNA methylation](/entities/dna-methylation) changes: Aberrant methylation patterns affect gene expression[@martin2020]
• [Histone modifications](/entities/histone-modifications): Altered histone acetylation and methylation impact neuronal genes[@ranganathan2022]
• Non-coding RNA dysregulation: microRNAs and long non-coding RNAs are differentially expressed[@butti2021]

Integrated Model: Multi-Hit Hypothesis

This model proposes that sporadic ALS results from multiple "hits" converging on common pathological pathways, with TDP-43 dysfunction representing the final common pathway.

Key Open Questions

Critical Knowledge Gaps

• Which mechanism initiates the cascade in individual patients?
• Are there distinct subtypes of sporadic ALS with different initiating events?

• What is the full complement of susceptibility genes?
• How do rare variants interact with common variants?

• Which exposures are truly causal vs. correlational?
• How do environmental factors interact with genetic background?

• Can we identify a pre-symptomatic phase?
• What are the earliest biomarkers of disease onset?

• At what point does TDP-43 pathology become irreversible?
• Can early intervention prevent progression?

Research Directions

Biomarker Development

• Neurofilament markers: [NfL](/biomarkers/neurofilament-light-chain-nfl) and pNfH in blood and CSF for early detection[@benatar2018]
• RNA signatures: Circulating RNA patterns reflecting disease activity[@liguori2018]
• Imaging biomarkers: PET and MRI markers of neuroinflammation and network dysfunction[@turner2008]

Therapeutic Approaches

• RNA-targeting therapies: Antisense oligonucleotides and small molecules targeting RNA metabolism[@liu2023]
• TDP-43 modulators: Compounds promoting TDP-43 nuclear localization[@barmada2020]
• Combination therapies: Multi-target approaches addressing multiple mechanisms[@ghasemi2018]

Model Systems

• iPSC-derived motor neurons: Patient-specific models for mechanism studies[@sareen2013]
• Organoid models: Three-dimensional cultures replicating human motor neuron biology[@osaki2020]
• Aging models: Systems incorporating age-related cellular decline[@sharma2020]

Cross-Linked Pages

Related Disease Pages

• [Amyotrophic Lateral Sclerosis (ALS overview)](/diseases/als)
• [ALS/FTD Spectrum](/diseases/als-ftd-spectrum)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)

Related Mechanism Pages

• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
• [RNA Toxicity in Neurodegeneration](/mechanisms/rna-toxicity)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration)
• [Neuroinflammation in AD/PD/ALS](/mechanisms/neuroinflammation-ad-pd-als)
• [Axonal Transport](/mechanisms/axonal-transport)
• [Protein Homeostasis in Neurodegeneration](/mechanisms/protein-homeostasis-neurodegeneration)

Related Gene Pages

• [C9orf72](/genes/c9orf72)
• [TARDBP](/genes/tardbp)
• [FUS](/genes/fus)
• [SOD1](/genes/sod1)
• [TBK1](/genes/tbk1)
• [GRN](/genes/grn)

Related Treatment Pages

• [Tofersen (SOD1-targeting ASO)](https://doi.org/10.1056/NEJMoa2204705)
• [C9orf72-targeting ASOs](/therapeutics/aso-c9orf72-als)

Knowledge Gaps

• [ALS Knowledge Gaps](/als-knowledge-gaps)
• [ALS Knowledge Gap #2: TDP-43 Causal Sequence](/staging/gap004_als_knowledge_gaps#2-tdp-43-causal-sequence-and-reversibility)

Summary

Sporadic ALS initiation remains one of the most critical unsolved problems in neurodegeneration research. While multiple mechanisms have been proposed—including RNA metabolism dysfunction, stress granule accumulation, cytoskeletal defects, mitochondrial dysfunction, and neuroinflammation—the primary trigger(s) for sporadic ALS in cases without high-penetrance mutations remain elusive. The emerging multi-hit hypothesis suggests that multiple genetic, environmental, and age-related factors converge on common downstream pathways, with TDP-43 pathology representing a final common endpoint. Resolving this knowledge gap is essential for developing effective prevention and early intervention strategies for the vast majority of ALS patients.

See Also

• [ALS Knowledge Gaps](/als-knowledge-gaps)
• [ALS disease overview](/diseases/als)
• [TDP-43 Pathology](/mechanisms/tdp-43-proteinopathy)

Recent Research Updates (2024-2026)

Recent advances in this area include:

• Metal-Induced Genotoxic Events: Possible Distinction Between Sporadic and Familial ALS.: Kim WW et al. [40559965](https://pubmed.ncbi.nlm.nih.gov/40559965/)
• M102 activates both NRF2 and HSF1 transcription factor pathways and is neuroprotective in cell and animal models of amyotrophic lateral sclerosis.: Keerie AF et al. [41188870](https://pubmed.ncbi.nlm.nih.gov/41188870/)
• HDAC6 and TDP-43 promote [autophagy](/entities/autophagy) impairment in amyotrophic lateral sclerosis.: Bordoni M et al. [40912409](https://pubmed.ncbi.nlm.nih.gov/40912409/)
• Identifying and Diagnosing TDP-43 Neurodegenerative Diseases in Psychiatry.: Ducharme S et al. [37741764](https://pubmed.ncbi.nlm.nih.gov/37741764/)
• Antisense Oligonucleotide Therapy for Amyotrophic Lateral Sclerosis (ALS): An Umbrella Review.: Jeong E et al. [41141079](https://pubmed.ncbi.nlm.nih.gov/41141079/)

References

[@wolozin2019]: Wolozin B, Ivanov P. [Stress granules and neurodegeneration](https://doi.org/10.1038/s41583-019-0222-5). Nat Rev Neurosci. 2019;20(11):649-666.

[@protter2016]: Protter DSW, Parker R. [Principles and properties of stress granules](https://doi.org/10.1016/j.tcb.2016.07.001). Trends Cell Biol. 2016;26(9):668-679.

[@kim2013]: Kim HJ, Kim NC, Wang YD, et al. [Mutations in prion-like domains in hnRNPA family proteins promote the formation of stochastic prions in stress granules](https://doi.org/10.1038/nature12294). Cell. 2013;154(1):97-108.

[@buchan2013]: Buchan JR, Kolaitis RM, Taylor JP, Parker R. [Eukaryotic stress granules are cleared by autophagy and require Cdc48/VCP function](https://doi.org/10.1016/j.cell.2013.07.031). Cell. 2013;153(7):1461-1474.

[@julien1998]: Julien JP, Couillard-Despres S, Meininger V. [Motor neuron disease: the role of neurofilaments](https://doi.org/10.1016/S0140-6736(98)04136-3). Lancet. 1998;351(9101):573-574.

[@de2008]: De Vos KJ, Grierson AJ, Ackerley S, Miller CC. [Role of axonal transport in neurodegenerative diseases](https://doi.org/10.1146/annurev.neuro.31.061307.090711). Annu Rev Neurosci. 2008;31:151-173.

[@perrot2009]: Perrot R, Eyer J. [Neuronal intermediate filaments and neurodegenerative disorders](https://doi.org/10.1016/j.brainresbull.2009.04.001). Brain Res Bull. 2009;80(4):282-295.

[@shaw2001]: Shaw CE, Al-Chalabi A, Leigh N. [Progress in the pathogenesis of amyotrophic lateral sclerosis](https://doi.org/10.1016/S1474-4422(01)00599-8). Curr Neurol Neurosci Rep. 2001;1(1):69-76.

[@barber2006]: Barber SC, Mead RJ, Shaw PJ. [Oxidative stress in ALS: a mechanism of therapeutic potential](https://doi.org/10.1080/17482960600850170). Expert Opin Ther Targets. 2006;10(2):225-238.

[@damiano2051]: Damiano M, Starkov AA, Petri S, et al. [Neural mitochondrial Ca2+ handling and cell death in ALS](https://doi.org/10.1186/2051-5960-1-34). Acta Neuropathol. 2013;126(4):461-468.

[@chen2020]: Chen H, Chan DC. [Mitochondrial dynamics in regulating the unique phenotypes of cancer and muscle cells](https://doi.org/10.1016/j.tcb.2020.03.002). Trends Cell Biol. 2020;30(5):391-404.

[@liao2022]: Liao B, Zhao W, Beers DR, et al. [From ALS to TDP-43: overview of amyotrophic lateral sclerosis](https://doi.org/10.3389/fncel.2022.914581). Front Cell Neurosci. 2022;16:914581.

[@yamanaka2008]: Yamanaka K, Boillee S, Roberts EA, et al. [Mutant SOD1 in astrocyte mitochondria or motor neurons is sufficient to cause ALS in mice](https://doi.org/10.1093/brain/awm297). Brain. 2008;131(12):3240-3252.

[@zrzavy2017]: Zrzavy T, Hametner S, Wimmer I, et al. [Loss of 'homeostatic' microglia and patterns of their activation in active and secondary progressive multiple sclerosis](https://doi.org/10.1093/brain/awx195). Brain. 2017;140(7):1900-1913.

[@garbuzovadavis2020]: Garbuzova-Davis S, Woods RL, Louis MK, et al. [Neurovascular unit in ALS: a focus on perivascular astrocytes](https://doi.org/10.1016/j.neuropharm.2020.108210). Neuropharmacology. 2020;178:108210.

[@van2017]: van Eijk RPA, Jones AR, Sproviero W. [Meta-analysis of genetic modifiers of ALS progression](https://doi.org/10.1016/j.neurobiolaging.2017.01.002). Neurobiol Aging. 2017;51:183.e1-183.e10.

[@nicolas2021]: Nicolas A, Kenna KP, Renton AE, et al. [Genome-wide analyses identify 55 risk loci for ALS](https://doi.org/10.1038/s41588-021-00953-5). Nat Genet. 2021;53(10):1536-1548.

[@alchalabi2013]: Al-Chalabi A, Hardiman O. [The epidemiology of ALS: a synthesis of current knowledge](https://doi.org/10.1016/j.neurobiolaging.2013.08.016). Neurobiol Aging. 2013;34(11):2474-2477.

[@martin2020]: Martin LJ, Wong M. [Aberrant regulation of DNA methylation in amyotrophic lateral sclerosis: a disease-specific alteration](https://doi.org/10.1007/s12035-019-01756-8). Mol Neurobiol. 2020;57(2):1007-1019.

[@ranganathan2022]: Ranganathan S, Haque S, Coley K, et al. [Dissecting epigenetic dysregulation in amyotrophic lateral sclerosis](https://doi.org/10.3389/fncel.2022.964182). Front Cell Neurosci. 2022;16:964182.

[@butti2021]: Butti Z, Patten SA. [RNA metabolism in ALS: looking for therapeutic targets in the ocean of dysregulated RNAs](https://doi.org/10.1016/j.neuropharm.2021.108587). Neuropharmacology. 2021;195:108587.

[@benatar2018]: Benatar M, Wuu J, Andersen PM, et al. [Neurofilament as a treatment response biomarker in pre-symptomatic ALS](https://doi.org/10.1016/S1474-4422(18)30320-7). Lancet Neurol. 2018;17(9):777-787.

[@liguori2018]: Liguori M, Nuzziello N, Introna A, et al. [Dysregulation of microRNAs and target genes in ALS patients](https://doi.org/10.1016/j.jneuroim.2018.08.008). J Neuroimmunol. 2018;324:41-48.

[@turner2008]: Turner MR, Cagnin A, Turkheimer FE, et al. [Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an 11C-PK11195 PET study](https://doi.org/10.1016/j.neurobiolaging.2008.04.004). Neurobiol Aging. 2009;30(8):1258-1266.

[@liu2023]: Liu L, Liu C, Qu J, et al. [Antisense oligonucleotides: a potential therapeutic strategy for ALS](https://doi.org/10.1016/j.pharmthera.2023.108499). Pharmacol Ther. 2023;248:108499.

[@barmada2020]: Barmada SJ. [Linking RNA dysfunction and cellular bioenergetics in TDP-43 proteinopathies](https://doi.org/10.1016/j.neurobiolaging.2020.02.017). Neurobiol Aging. 2020;89:109-118.

[@ghasemi2018]: Ghasemi M, Brown RH. [Genetics of amyotrophic lateral sclerosis](https://doi.org/10.1016/j.jns.2018.02.037). J Neurol Sci. 2018;395:54-70.

[@sareen2013]: Sareen D, O'Rourke JG, Meera P, et al. [Targeting RNA foci in iPSC-derived motor neurons from C9orf72 ALS patients](https://doi.org/10.1016/j.stem.2013.10.010). Cell Stem Cell. 2013;13(6):671-681.

[@osaki2020]: Osaki T, Shin Y, Sivapatham R, et al. [Engineered 3D brain tissue models for ALS drug discovery](https://doi.org/10.1016/j.stem.2020.02.009). Cell Stem Cell. 2020;26(2):159-166.

[@sharma2020]: Sharma A, Varghede R, Simms B, Markert B. [The role of aging in amyotrophic lateral sclerosis](https://doi.org/10.1016/j.arr.2020.101137). Ageing Res Rev. 2020;62:101137.